Getinge AB ser. B (GETI-B) - Net Assets
Based on the latest financial reports, Getinge AB ser. B (GETI-B) has net assets worth Skr29.49 Billion SEK (≈ $3.17 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr56.51 Billion ≈ $6.08 Billion USD) and total liabilities (Skr27.01 Billion ≈ $2.91 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Getinge AB ser. B liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr29.49 Billion |
| % of Total Assets | 52.2% |
| Annual Growth Rate | 10.2% |
| 5-Year Change | 17.15% |
| 10-Year Change | 41.01% |
| Growth Volatility | 13.66 |
Getinge AB ser. B - Net Assets Trend (2002–2025)
This chart illustrates how Getinge AB ser. B's net assets have evolved over time, based on quarterly financial data. Also explore GETI-B current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Getinge AB ser. B (2002–2025)
The table below shows the annual net assets of Getinge AB ser. B from 2002 to 2025. For live valuation and market cap data, see Getinge AB ser. B market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr29.49 Billion ≈ $3.17 Billion |
-11.19% |
| 2024-12-31 | Skr33.21 Billion ≈ $3.57 Billion |
+9.23% |
| 2023-12-31 | Skr30.40 Billion ≈ $3.27 Billion |
-0.16% |
| 2022-12-31 | Skr30.45 Billion ≈ $3.28 Billion |
+20.96% |
| 2021-12-31 | Skr25.18 Billion ≈ $2.71 Billion |
+17.17% |
| 2020-12-31 | Skr21.49 Billion ≈ $2.31 Billion |
+2.45% |
| 2019-12-31 | Skr20.97 Billion ≈ $2.26 Billion |
+6.71% |
| 2018-12-31 | Skr19.66 Billion ≈ $2.12 Billion |
-0.76% |
| 2017-12-31 | Skr19.81 Billion ≈ $2.13 Billion |
-5.31% |
| 2016-12-31 | Skr20.92 Billion ≈ $2.25 Billion |
+6.75% |
| 2015-12-31 | Skr19.59 Billion ≈ $2.11 Billion |
+4.81% |
| 2014-12-31 | Skr18.69 Billion ≈ $2.01 Billion |
+12.89% |
| 2013-12-31 | Skr16.56 Billion ≈ $1.78 Billion |
+8.95% |
| 2012-12-31 | Skr15.20 Billion ≈ $1.64 Billion |
+3.85% |
| 2011-12-31 | Skr14.64 Billion ≈ $1.58 Billion |
+10.48% |
| 2010-12-31 | Skr13.25 Billion ≈ $1.43 Billion |
+5.46% |
| 2009-12-31 | Skr12.56 Billion ≈ $1.35 Billion |
+17.67% |
| 2008-12-31 | Skr10.68 Billion ≈ $1.15 Billion |
+61.20% |
| 2007-12-31 | Skr6.62 Billion ≈ $712.74 Million |
+10.29% |
| 2006-12-31 | Skr6.00 Billion ≈ $646.23 Million |
+11.59% |
| 2005-12-31 | Skr5.38 Billion ≈ $579.11 Million |
+26.04% |
| 2004-12-31 | Skr4.27 Billion ≈ $459.48 Million |
+20.94% |
| 2003-12-31 | Skr3.53 Billion ≈ $379.93 Million |
+11.79% |
| 2002-12-31 | Skr3.16 Billion ≈ $339.87 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Getinge AB ser. B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1819.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr21.50 Billion | 73.07% |
| Common Stock | Skr136.00 Million | 0.46% |
| Other Comprehensive Income | Skr1.00 Billion | 3.40% |
| Other Components | Skr6.79 Billion | 23.07% |
| Total Equity | Skr29.43 Billion | 100.00% |
Getinge AB ser. B Competitors by Market Cap
The table below lists competitors of Getinge AB ser. B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KEI Industries Limited
NSE:KEI
|
$5.02 Billion |
|
CHINA TOWER UNSP.ADR/100
F:2Y10
|
$5.02 Billion |
|
EVN AG
VI:EVN
|
$5.03 Billion |
|
INPOST S.A. EO -01
F:669
|
$5.03 Billion |
|
Corporacion Financiera Alba SA
MC:ALB
|
$5.02 Billion |
|
Phillips Edison & Co Inc
NASDAQ:PECO
|
$5.02 Billion |
|
PI Industries Limited
NSE:PIIND
|
$5.01 Billion |
|
Minth Group Limited
F:M3I
|
$5.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Getinge AB ser. B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 33,005,000,000 to 29,429,000,000, a change of -3,576,000,000 (-10.8%).
- Net income of 2,258,000,000 contributed positively to equity growth.
- Dividend payments of 1,253,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 4,752,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr2.26 Billion | +7.67% |
| Dividends Paid | Skr1.25 Billion | -4.26% |
| Other Comprehensive Income | Skr-4.75 Billion | -16.15% |
| Other Changes | Skr171.00 Million | +0.58% |
| Total Change | Skr- | -10.83% |
Book Value vs Market Value Analysis
This analysis compares Getinge AB ser. B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.70x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.87x to 1.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr14.26 | Skr183.55 | x |
| 2003-12-31 | Skr15.94 | Skr183.55 | x |
| 2004-12-31 | Skr19.06 | Skr183.55 | x |
| 2005-12-31 | Skr23.96 | Skr183.55 | x |
| 2006-12-31 | Skr27.01 | Skr183.55 | x |
| 2007-12-31 | Skr29.50 | Skr183.55 | x |
| 2008-12-31 | Skr47.63 | Skr183.55 | x |
| 2009-12-31 | Skr49.60 | Skr183.55 | x |
| 2010-12-31 | Skr52.31 | Skr183.55 | x |
| 2011-12-31 | Skr57.79 | Skr183.55 | x |
| 2012-12-31 | Skr60.01 | Skr183.55 | x |
| 2013-12-31 | Skr65.40 | Skr183.55 | x |
| 2014-12-31 | Skr72.56 | Skr183.55 | x |
| 2015-12-31 | Skr75.97 | Skr183.55 | x |
| 2016-12-31 | Skr84.82 | Skr183.55 | x |
| 2017-12-31 | Skr77.31 | Skr183.55 | x |
| 2018-12-31 | Skr70.50 | Skr183.55 | x |
| 2019-12-31 | Skr75.25 | Skr183.55 | x |
| 2020-12-31 | Skr77.19 | Skr183.55 | x |
| 2021-12-31 | Skr90.87 | Skr183.55 | x |
| 2022-12-31 | Skr110.28 | Skr183.55 | x |
| 2023-12-31 | Skr110.75 | Skr183.55 | x |
| 2024-12-31 | Skr121.18 | Skr183.55 | x |
| 2025-12-31 | Skr108.05 | Skr183.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Getinge AB ser. B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.67%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.46%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.92x
- Recent ROE (7.67%) is below the historical average (12.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 19.69% | 7.20% | 0.91x | 3.00x | Skr305.88 Million |
| 2003 | 22.03% | 8.49% | 0.76x | 3.41x | Skr424.66 Million |
| 2004 | 27.20% | 10.54% | 0.87x | 2.95x | Skr725.74 Million |
| 2005 | 21.45% | 9.58% | 0.82x | 2.74x | Skr607.66 Million |
| 2006 | 20.96% | 9.65% | 0.82x | 2.65x | Skr655.70 Million |
| 2007 | 19.10% | 7.66% | 0.72x | 3.48x | Skr600.20 Million |
| 2008 | 14.30% | 7.90% | 0.58x | 3.10x | Skr457.80 Million |
| 2009 | 15.27% | 8.39% | 0.61x | 2.99x | Skr660.20 Million |
| 2010 | 17.22% | 10.27% | 0.64x | 2.62x | Skr954.70 Million |
| 2011 | 17.31% | 11.57% | 0.53x | 2.84x | Skr1.07 Billion |
| 2012 | 16.62% | 10.40% | 0.56x | 2.83x | Skr1.00 Billion |
| 2013 | 13.82% | 9.04% | 0.57x | 2.68x | Skr631.90 Million |
| 2014 | 7.81% | 5.37% | 0.50x | 2.88x | Skr-401.20 Million |
| 2015 | 7.24% | 4.60% | 0.57x | 2.77x | Skr-530.30 Million |
| 2016 | 5.79% | 3.99% | 0.54x | 2.69x | Skr-862.80 Million |
| 2017 | 7.10% | 6.12% | 0.53x | 2.17x | Skr-562.40 Million |
| 2018 | -5.04% | -4.00% | 0.56x | 2.26x | Skr-2.89 Billion |
| 2019 | 5.96% | 4.60% | 0.59x | 2.18x | Skr-827.60 Million |
| 2020 | 15.41% | 10.86% | 0.66x | 2.14x | Skr1.14 Billion |
| 2021 | 12.00% | 10.98% | 0.61x | 1.80x | Skr495.10 Million |
| 2022 | 8.29% | 8.80% | 0.54x | 1.73x | Skr-512.80 Million |
| 2023 | 8.00% | 7.58% | 0.59x | 1.78x | Skr-604.60 Million |
| 2024 | 4.96% | 4.71% | 0.54x | 1.94x | Skr-1.66 Billion |
| 2025 | 7.67% | 6.46% | 0.62x | 1.92x | Skr-684.90 Million |
Industry Comparison
This section compares Getinge AB ser. B's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Getinge AB ser. B (GETI-B) | Skr29.49 Billion | 19.69% | 0.92x | $5.02 Billion |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Getinge AB ser. B
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solu… Read more